FODMAP Diet Beats General Dietary Advice for IBS

This article originally appeared here.
Share this content:
FODMAP Diet Beats General Dietary Advice for IBS
FODMAP Diet Beats General Dietary Advice for IBS

THURSDAY, Nov. 30, 2017 (HealthDay News) -- While both improve gastrointestinal symptoms, the low Fermentable Oligo-Di-Mono-saccharides and polyols (FODMAP) diet shows greater benefit for patients with irritable bowel syndrome (IBS) than general dietary advice (GDA), according to a study published online Nov. 20 in the Journal of Gastroenterology and Hepatology.

Mohammad Javad Zahedi, M.D., from the Kerman University of Medical Sciences in Iran, and colleagues compared the impact of diets on the clinical response in patients with diarrhea subtype of IBS (IBS-D). Participants were randomized to low FODMAP (55 patients) and GDA (55 patients) for six weeks after a 10-day screening period.

The researchers found that after six weeks, the low FODMAP diet significantly improved overall gastrointestinal symptom scores (P < 0.001), stool frequency (P < 0.001), and stool consistency (P = 0.003), compared to the GDA group. At the end of the study period, both intervention groups expressed a significant reduction in overall scores of the IBS-severity scoring system questionnaire, abdominal pain, distension, consistency, and frequency, although this reduction was greater in the low FODMAP diet group.

"Both low FODMAP diet and GDA in patients with IBS-D led to adequate improvement of gastrointestinal symptoms for six weeks," the authors write. "However, the low FODMAP diet has greater benefits in IBS improvement."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »